Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gin Hwa BiotechROCO:7806 22 Operating Margin % is 11.54% as of Dec. 2025, which is 46% below its 10-year median of 21.54. GuruFocus rates ROCO:7806 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Gin Hwa Biotech ranks better than 86.38% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Gin Hwa Biotech Operating Margin % Related Terms
Gin Hwa Biotech Operating Margin % Historical Data
* Premium members only.
The historical data trend for Gin Hwa Biotech's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7806 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Gin Hwa Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gin Hwa Biotech Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gin Hwa Biotech's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Gin Hwa Biotech's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Gin Hwa Biotech's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gin Hwa Biotech (ROCO:7806) has a Operating Margin % of 11.54% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Gin Hwa Biotech and its competitors. This is 46% below median its historical median of 21.54. Over the past decade, Gin Hwa Biotech's Operating Margin % has ranged from 17.07 to 25.52. According to the industry distribution chart, Gin Hwa Biotech ranks #128 out of 940 companies in the Biotechnology industry, placing it in the top 13.6%.
Is Gin Hwa Biotech's Operating Margin % too high?
Gin Hwa Biotech's current Operating Margin % of 11.54% is 46% below median its 10-year median of 21.54. Over the past 10 years, this metric has ranged from a low of 17.07 to a high of 25.52. Based on the distribution chart, Gin Hwa Biotech ranks #128 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gin Hwa Biotech ranks #128 out of 940 companies for Operating Margin %. This places Gin Hwa Biotech in the top 14% of its industry — outperforming the majority of peers. Historically, Gin Hwa Biotech's own Operating Margin % has ranged from 17.07 to 25.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Gin Hwa Biotech and its competitors. Gin Hwa Biotech's current Operating Margin % is 11.54%, which is 46% below median its own 10-year median of 21.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current Operating Margin % of 11.54%. The current Operating Margin % is 11.54%, which is 46% below median its 10-year median of 21.54. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current Operating Margin % is 11.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score
Get the complete analysis for ROCO:7806
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7806 has been successfully added to your 
